N/A
Completed N=50
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Medication Adherence · Glaucoma
Source: ClinicalTrials.gov NCT03506568 ↗
Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Feb 2023
Primary outcomePrimary: Compliance Percentage — 73.9; 94.6; 93.99 percentage of days dose monitor recorded
Summary
Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective. However, adherence to eye drop treatment is poor with only 50% of patients regularly taking their prescribed eye drops. The investigators are developing the Devers Drop Device (D3) eye drop monitor to accurately measure eye drop cap removal and to improve eye drop-taking behavior. The investigators will test eye drop adherence with the D3 device in a randomized, prospective clinical trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Compliance Percentage |
73.9; 94.6; 93.99 | — |
| SECONDARY Patient Satisfaction |
17; 22.5; 22.1 | — |
Eligibility Criteria
Inclusion Criteria
- Patients who are prescribed latanoprost eye drop to be used once per day at bedtime, and own a functioning smartphone and have a password-protected home wireless connection.
Exclusion Criteria
- Patients who currently use smartphone medication reminders and those with severe cognitive impairment limiting their ability to understand a questionnaire.
Data sourced from ClinicalTrials.gov (NCT03506568). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.